Status: Recruiting
A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19/BCMA CAR-T in the treatment of refractory autoimmune diseases.
Participants needed: 20
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Liang ZouUpdated: Jul 27, 2026Locations: 3
Eligibility criteria
Age: 18~70 years old, male or female; provided written informed consent form (IC... [+20]
Prior treatment with CAR-T cell therapy; [+9]